Early-stage Uterine Pure and Mixed Clear Cell Carcinoma: Outcomes and Recurrence With and Without Adjuvant Therapy
暂无分享,去创建一个
[1] Sharon M. Lu,et al. Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma. , 2015, Gynecologic oncology.
[2] H. Ashamalla,et al. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry , 2015, Journal of gynecologic oncology.
[3] Rochelle L. Garcia,et al. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers , 2015, Journal of gynecologic oncology.
[4] R. Pai,et al. Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer , 2014, The American journal of surgical pathology.
[5] Jen-Ruei Chen,et al. Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study. , 2014, Gynecologic oncology.
[6] J. Debus,et al. Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy , 2014, Radiation oncology.
[7] C. Chang-Halpenny,et al. Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy. , 2013, Gynecologic oncology.
[8] Tina A. Ayeni,et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. , 2013, Gynecologic oncology.
[9] R. Berkowitz,et al. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer. , 2013, Gynecologic oncology.
[10] Jeong-Won Lee,et al. A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system , 2013, Journal of gynecologic oncology.
[11] R. Yechieli,et al. Adjuvant Radiation Therapy for Patients With Type II Endometrial Carcinoma: Impact on Tumor Recurrence and Survival , 2013, International Journal of Gynecologic Cancer.
[12] R. Barakat,et al. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. , 2012, Gynecologic oncology.
[13] Rochelle L. Garcia,et al. A contemporary analysis of clear cell carcinoma of the endometrium , 2012 .
[14] J. Lea,et al. Survival outcomes after recurrence in endometrioid compared to papillary serous/clear cell carcinoma of the uterus , 2012 .
[15] M. Rotman,et al. Impact of adjuvant external-beam radiation therapy in early-stage uterine papillary serous and clear cell carcinoma. , 2011, International journal of radiation oncology, biology, physics.
[16] J. Ranstam,et al. Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma. , 2010, Anticancer research.
[17] P. Radice,et al. Lynch Syndrome—Related Endometrial Carcinomas Show a High Frequency of Nonendometrioid Types and of High FIGO Grade Endometrioid Types , 2010, International journal of surgical pathology.
[18] A. Olawaiye,et al. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.
[19] D. Mutch,et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. , 2008, Gynecologic oncology.
[20] P. Maisonneuve,et al. Carcinoma of the corpus uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[21] A. Mundt,et al. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. , 2003, International journal of radiation oncology, biology, physics.
[22] Brady J. McKee,et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous (PS)/clear cell (CC) histologies and endometrioid FIGO grade 3 , 2001 .
[23] P. Koper,et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.
[24] V. Abeler,et al. Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern , 1996, Cancer.
[25] D. Edelman,et al. Clear cell carcinoma of the endometrium , 1979, Cancer.
[26] A. Mariani,et al. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. , 2013, International journal of radiation oncology, biology, physics.
[27] J. Hecht,et al. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. , 2013, American journal of cancer research.
[28] T. Goto,et al. Prognosis of high-grade endometrial cancer: a comparison of serous-type and clear cell type to grade 3 endometrioid-type. , 2012, European journal of gynaecological oncology.
[29] N. Horowitz,et al. A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. , 2010, European journal of gynaecological oncology.
[30] S. Lo,et al. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience. , 2010, Brachytherapy.
[31] M. Usel,et al. Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. , 2008, European journal of gynaecological oncology.